Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 09203E105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| BlackRock, Inc. 13G | 6.7% |
7/27/2026
Event 6/30/2026
|
|
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 4 | 7.0% |
7/8/2026
Event 6/30/2026
|
|
|
Vestal Point Capital, LP
13G/A
Amendment 1
|
1.5% |
2/17/2026
Event 12/31/2025
|
|
| Vestal Point Capital, LP | 1.5% | ||
| Ryan Wilder | 1.5% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.5% |
4/29/2025
Event 3/31/2025
|
|
|
BB Biotech AG
13G/A
Amendment 6
|
4.8% |
3/21/2025
Event 3/19/2025
|
|
| BB Biotech AG | 4.8% | ||
| Biotech Growth N.V. | 4.8% | ||
|
BB Biotech AG
13G/A
Amendment 5
|
15.1% |
2/14/2025
Event 12/31/2024
|
|
| BB Biotech AG | 15.1% | ||
| Biotech Growth N.V. | 15.1% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 19.9 k | $37.4 k |
| 2026 Q2 | 103 | 35.0 M | $64.9 M |
| 2026 Q1 | 109 | 38.5 M | $82.0 M |
| 2025 Q4 | 114 | 40.2 M | $97.8 M |
| 2025 Q3 | 93 | 38.8 M | $147 M |
| 2025 Q2 | 96 | 38.7 M | $96.1 M |
| 2025 Q1 | 92 | 40.8 M | $66.3 M |
| 2024 Q4 | 93 | 47.9 M | $103 M |
| 2024 Q3 | 117 | 48.7 M | $212 M |
| 2024 Q2 | 100 | 47.0 M | $219 M |
| 2024 Q1 | 95 | 39.6 M | $201 M |
| 2023 Q4 | 84 | 39.0 M | $110 M |
| 2023 Q3 | 79 | 37.2 M | $107 M |
| 2023 Q2 | 83 | 41.4 M | $209 M |
| 2023 Q1 | 54 | 21.5 M | $40.6 M |
| 2022 Q4 | 64 | 21.1 M | $38.0 M |
| 2022 Q3 | 74 | 21.5 M | $36.3 M |
| 2022 Q2 | 80 | 21.5 M | $52.9 M |
| 2022 Q1 | 92 | 22.9 M | $64.1 M |
| 2021 Q4 | 102 | 23.2 M | $124 M |
| 2021 Q3 | 106 | 24.4 M | $206 M |
| 2021 Q2 | 109 | 25.4 M | $310 M |
| 2021 Q1 | 119 | 29.1 M | $706 M |
| 2020 Q4 | 113 | 28.6 M | $917 M |
| 2020 Q3 | 90 | 23.8 M | $718 M |
| 2020 Q2 | 81 | 23.1 M | $968 M |
| 2020 Q1 | 68 | 22.3 M | $556 M |